These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 30938262)
1. Diversity of phenotypically non-dermatophyte, non-Aspergillus filamentous fungi causing nail infections: importance of accurate identification and antifungal susceptibility testing. Tsang CC; Tang JYM; Chan KF; Lee CY; Chan JFW; Ngan AHY; Cheung M; Lau ECL; Li X; Ng RHY; Lai CKC; Fung KSC; Lau SKP; Woo PCY Emerg Microbes Infect; 2019; 8(1):531-541. PubMed ID: 30938262 [TBL] [Abstract][Full Text] [Related]
2. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis. Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354 [TBL] [Abstract][Full Text] [Related]
3. In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium. Sarifakioglu E; Seçkin D; Demirbilek M; Can F Clin Exp Dermatol; 2007 Nov; 32(6):675-9. PubMed ID: 17714532 [TBL] [Abstract][Full Text] [Related]
4. Molecular characterization and antifungal activity against non-dermatophyte molds causing onychomycosis. Pakshir K; Kamali M; Nouraei H; Zomorodian K; Motamedi M; Mahmoodi M Sci Rep; 2021 Oct; 11(1):20736. PubMed ID: 34671053 [TBL] [Abstract][Full Text] [Related]
5. Characterization of the antimicrobial susceptibility of fungi responsible for onychomycosis in Spain. Zalacain A; Obrador C; Martinez JP; Viñas M; Vinuesa T Med Mycol; 2011 Jul; 49(5):495-9. PubMed ID: 21142899 [TBL] [Abstract][Full Text] [Related]
6. In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. Gupta AK; Kohli Y; Batra R Med Mycol; 2005 Mar; 43(2):179-85. PubMed ID: 15832561 [TBL] [Abstract][Full Text] [Related]
7. Prevalence and epidemiology of tinea pedis and toenail onychomycosis and antifungal susceptibility of the causative agents in patients with type 2 diabetes in Turkey. Oz Y; Qoraan I; Oz A; Balta I Int J Dermatol; 2017 Jan; 56(1):68-74. PubMed ID: 27667305 [TBL] [Abstract][Full Text] [Related]
8. Clinico-mycological study of onychomycosis and in vitro antifungal susceptibility of Trichophyton rubrum. Huang X; Wang Q; Yan QH; Feng S; Zhang GQ; Yuan XY Eur J Dermatol; 2024 Jun; 34(3):260-266. PubMed ID: 39015959 [TBL] [Abstract][Full Text] [Related]
9. In vitro biofilms and antifungal susceptibility of dermatophyte and non-dermatophyte moulds involved in foot mycosis. Toukabri N; Corpologno S; Bougnoux ME; El Euch D; Sadfi-Zouaoui N; Simonetti G Mycoses; 2018 Feb; 61(2):79-87. PubMed ID: 28940733 [TBL] [Abstract][Full Text] [Related]
10. Onychomycosis: clinical, mycological and in vitro susceptibility testing of isolates of Trichophyton rubrum. Azambuja CV; Pimmel LA; Klafke GB; Xavier MO An Bras Dermatol; 2014; 89(4):581-6. PubMed ID: 25054744 [TBL] [Abstract][Full Text] [Related]
11. Antifungal susceptibility patterns of yeasts and filamentous fungi isolated from nail infection. Ataides FS; Chaul MH; El Essal FE; Costa CR; Souza LK; Fernandes OF; Silva MR J Eur Acad Dermatol Venereol; 2012 Dec; 26(12):1479-85. PubMed ID: 22049990 [TBL] [Abstract][Full Text] [Related]
12. In vitro antifungal susceptibility testing of fungi in patients with onychomycosis. Abu El-Hamd M; Abd Elhameed MI; Shalaby MFM; Saleh R Dermatol Ther; 2020 May; 33(3):e13429. PubMed ID: 32304603 [TBL] [Abstract][Full Text] [Related]
13. Onychomycosis insensitive to systemic terbinafine and azole treatments reveals non-dermatophyte moulds as infectious agents. Baudraz-Rosselet F; Ruffieux C; Lurati M; Bontems O; Monod M Dermatology; 2010; 220(2):164-8. PubMed ID: 20110639 [TBL] [Abstract][Full Text] [Related]
14. Combinatorial effect of fluconazole, itraconazole, and terbinafine with different culture extracts of Candida parapsilosis and Trichophyton spp. against Trichophyton rubrum. Lemes TH; Nascentes JAS; Regasini LO; Siqueira JPZ; Maschio-Lima T; Pattini VC; Ribeiro MD; de Almeida BG; de Almeida MTG Int Microbiol; 2024 Jun; 27(3):899-905. PubMed ID: 37875749 [TBL] [Abstract][Full Text] [Related]
15. A Mycological and Molecular Epidemiologic Study on Onychomycosis and Determination Halvaee S; Daie-Ghazvini R; Hashemi SJ; Khodavaisy S; Rahimi-Foroushani A; Bakhshi H; Rafat Z; Ardi P; Abastabar M; Zareei M; Borjian-Boroujeni Z; Kamali Sarvestani H Front Cell Infect Microbiol; 2021; 11():693522. PubMed ID: 34336717 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Gupta AK; Gregurek-Novak T Dermatology; 2001; 202(3):235-8. PubMed ID: 11385230 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of antifungal agents in onychomycoses. Debruyne D; Coquerel A Clin Pharmacokinet; 2001; 40(6):441-72. PubMed ID: 11475469 [TBL] [Abstract][Full Text] [Related]
18. Molecular identification and antifungal susceptibility of clinical fungal isolates from onychomycosis (uncommon and emerging species). Haghani I; Shams-Ghahfarokhi M; Dalimi Asl A; Shokohi T; Hedayati MT Mycoses; 2019 Feb; 62(2):128-143. PubMed ID: 30255665 [TBL] [Abstract][Full Text] [Related]
19. Non-dermatophytes in onychomycosis of the toenails. Ellis DH; Watson AB; Marley JE; Williams TG Br J Dermatol; 1997 Apr; 136(4):490-3. PubMed ID: 9155945 [TBL] [Abstract][Full Text] [Related]
20. Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis. Carrillo-Muñoz AJ; Giusiano G; Cárdenes D; Hernández-Molina JM; Eraso E; Quindós G; Guardia C; del Valle O; Tur-Tur C; Guarro J Int J Antimicrob Agents; 2008 Jun; 31(6):540-3. PubMed ID: 18367383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]